Traders should monitor the upcoming ELPIS II trial results for HLHS in Q3 2026, the company's ability to maintain Nasdaq listing, and whether it can secure additional funding. The stock faces significant downside risk due to financial instability and regulatory compliance issues.
Executive Summary
Longeveron Inc. (LGVN) is registering 30.9 million shares for resale by selling stockholders, including shares from a recent private placement and convertible preferred stock. The company is a clinical-stage biotech advancing its lead therapy laromestrocel for rare diseases, but faces going concern risks and Nasdaq listing compliance issues. While it recently raised $15.9 million, it needs additional funding and has a weak cash position.
Key Facts
- Company is registering 30,865,385 shares for resale by selling stockholders, including 6.0 million shares issued and 22.8 million shares issuable upon conversion of preferred stock
- Laromestrocel is in clinical development for Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty
- Company received a going concern opinion from auditors due to working capital deficiency, stockholders' deficit, and recurring losses
- Nasdaq has issued a minimum bid price deficiency notice, and the company has until September 21, 2026 to regain compliance
- Recent private placement raised approximately $15.9 million in gross proceeds before fees
- The company plans to use any proceeds from warrant exercises for clinical development and working capital
Financial Impact
Up to $1.3 million if all placement agent warrants are exercised, but no proceeds to company from the share resale registration
Risk Factors
- Going concern risk due to working capital deficiency and recurring losses
- Nasdaq delisting risk if minimum bid price requirement is not met by September 2026
- Significant dilution from outstanding warrants and convertible preferred stock
- Dependence on successful clinical trial outcomes for survival
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001213900-26-042461 |
| Document: ea028582701ex5-1.htm | 0001213900-26-042461 |
| Document: ea028582701ex-fee.htm | 0001213900-26-042461 |
| Document: ea028582701ex23-2.htm | 0001213900-26-042461 |
| Document: ea028582701ex23-1.htm | 0001213900-26-042461 |
| Document: 0001213900-26-042461-index-headers.html | 0001213900-26-042461 |
| Document: 0001213900-26-042461-index.html | 0001213900-26-042461 |
| Document: 0001213900-26-042461.txt | 0001213900-26-042461 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 8-K | $6.86 $2.49 | ▼ −63.70% | ▼ −64.52% | $2.57 (−62.61%) |
Jul 13, 2026 11w ago | 3 | $0.6223 $0.6022 | ▼ −3.23% | ▼ −1.93% | $2.57 (+312.18%) |
Jun 5, 2026 16w ago | 8-K | $0.7540 $0.7900 | ▲ +4.77% | ▲ +2.66% | $2.57 (+240.19%) |
May 20, 2026 19w ago | Press Release | $0.7210 $0.8150 | ▲ +13.04% | ▲ +11.44% | $2.57 (+255.76%) |
May 13, 2026 20w ago | 8-K | $0.7030 $0.7210 | ▲ +2.56% | ▲ +3.28% | $2.57 (+264.86%) |
May 8, 2026 20w ago | 8-K | $0.8380 $0.6760 | ▲ +19.33% | ▲ +19.25% | $2.57 (−206.09%) |
Apr 20, 2026 23w ago | EFFECT | $1.04 $0.9000 | ▲ +13.46% | ▲ +14.37% | $2.57 (−146.63%) |
Apr 10, 2026 24w ago | 8-K | $1.12 $1.04 | ▼ −7.14% | ▼ −10.44% | $2.57 (+129.02%) |
Apr 10, 2026 24w ago | S-1 | $1.12 $1.04 | ▲ +7.14% | ▲ +10.44% | $2.57 (−129.02%) |
Mar 17, 2026 28w ago | Press Release | $0.9760 $0.9730 | ▲ +0.31% | ▼ −0.41% | $2.57 (−162.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access